Eaton Corporation plc vs Johnson & Johnson — how do they compare? Eaton Corporation plc trades at $397.76 (market cap $160.31B), while Johnson & Johnson trades at $249.9 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 3.7× Eaton Corporation plc's market cap, and Johnson & Johnson pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| ETN | JNJ | |
|---|---|---|
Market Cap | $160.31B | $594.63B |
Sector | Technology | Health |
52-Week High | $435.78 | $267.24 |
52-Week Low | $315.82 | $162.98 |
Enterprise Value | $181.40B | $627.57B |
Dividend Yield | 1.07% | 2.17% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $395.5, down 4.82% over 24 hours, but remains near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $392. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding the $2.73 estimate. Revenue for 2025 reached $27.45 billion, with a net income margin of 13.99%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $449.50 and 64.1% of analysts rating it a Buy.
The outlook for ETN is favorable, driven by strong demand in data center power infrastructure and recent strategic acquisitions. However, risks include elevated valuation multiples like a P/E of 40.4 and potential macroeconomic pressures on industrial spending. The stock offers upside to the consensus target but requires monitoring of execution on growth initiatives and competitive dynamics in the power management sector.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Trailing returns across standard periods
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →